MAITRI.BO · BSE
Maitri Enterprises Limited
₹37.5
+0.00% (₹0)
Prev. close
₹37.5
Volume
50
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Maitri Enterprises Limited
Maitri Enterprises Limited primarily engages in the trading of pharmaceutical and medical goods in India. The company operates through two segments: Pharmaceutical Goods and Infrastructure and Real Estate. The company also engages in the sale of services by way of a works contract. The company also offers office spaces, residential, retail leasing, and green developments. The company was formerly known as Parth Alluminium Limited and changed its name to Maitri Enterprises Limited in December 2016. Maitri Enterprises Limited was incorporated in 1991 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Pharmaceutical Retailers
CEO
Mr. Jaikishan Rameshlal Ambwani
Headquarters
Ahmedabad
Employees
22
Website
maitrienterprises.comExchange
View on BSE ↗Key stats
Market cap
₹16.50 Cr
P/E ratio (TTM)
19.7
EPS (TTM)
₹1.90
Beta (1Y · daily vs NIFTY 50)
0.06
Beta (5Y · monthly vs NIFTY 50)
0.84
Shares float
14.09 L
EPS · quarter ended Jun 2026
₹-1.05
Financial Performance
01 · Financials
The first plotted growth figure is computed against Mar 2022 revenue as filed with BSE; the two sources' revenue definitions differ by 0.2% on Mar 2023. FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ₹19.72 Cr | ₹13.30 Cr | ₹19.01 Cr | ₹28.66 Cr | ₹33.30 Cr | |
| EBITDA | ₹71.50 L | ₹59.32 L | ₹36.39 L | ₹1.14 Cr | ₹1.69 Cr |
| ₹22.60 L | ₹-11,000 | ₹-44.95 L | ₹16.88 L | ₹60.43 L | |
| Diluted EPS | — | ₹-0 | ₹-1.02 | ₹0.38 | ₹1.37 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹18.39 Cr | ₹21.67 Cr | ₹16.36 Cr | ₹14.64 Cr | |
| — | ₹6.34 Cr | ₹10.55 Cr | ₹6.89 Cr | ₹4.83 Cr | |
| Stockholders' equity | — | ₹4.97 Cr | ₹4.52 Cr | ₹4.70 Cr | ₹5.26 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹2.38 L | ₹6.40 L | ₹3.04 Cr | ₹3.09 Cr | |
| Investing cash flow | — | ₹-24.38 L | ₹-3.45 Cr | ₹1.23 Cr | ₹-23.66 L |
| — | ₹24.35 L | ₹3.49 Cr | ₹-4.40 Cr | ₹-2.76 Cr | |
| Capital expenditure | — | ₹-3.06 L | ₹-6.37 L | ₹-7.95 L | ₹-23.02 L |
| End cash position | — | ₹44.51 L | ₹54.72 L | ₹42.52 L | ₹51.36 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Maitri Enterprises Limited | ₹16.50 Cr | ₹37.5 | 19.7 | 3.14 | 11.5% | 0.92 | +16.2% | -7.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 19
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.